UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2019

Commission File Number: 001-37452

 

 

CELYAD SA

(Translation of registrant’s name into English)

 

 

Rue Edouard Belin 2

1435 Mont-Saint-Guibert, Belgium

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


Celyad SA

On January 7, 2019, Celyad S.A. (the “ Company ”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company will be conducting meetings with investors attending the 37th Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 7, 2019. As part of these meetings, the Company will deliver the slide presentation furnished to this report as Exhibit 99.2 and which is incorporated herein by reference.

The information in this report included as Exhibit 99.1 and Exhibit 99.2 and incorporated herein by reference shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to this report.


EXHIBITS

 

Exhibit

  

Description

99.1    Press release issued by the registrant on January 7, 2019
99.2    Investor presentation furnished by Celyad S.A.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    CELYAD SA
Date: January 7, 2019     By:  

/s/ Filippo Petti

     

Filippo Petti

Chief Financial Officer

Exhibit 99.1

 

LOGO

  

Press Release

07 January 2019

7:00am CET

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

 

 

 

   

Lead candidate CYAD-01 continues to demonstrate encouraging clinical activity in THINK Phase 1 trial with a new complete response (CR) observed in patient with myelodysplastic syndrome (MDS)

 

   

Key focus to accelerate the development of CYAD-01 for the treatment of patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) or MDS, including the initiation of a Phase 2 clinical trial during second half 2019

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that it is accelerating its clinical development strategy for AML and MDS and provided updates on clinical candidates CYAD-01 and CYAD-101 with key upcoming milestones for 2019.

“We made progress in 2018 with our CAR-T clinical programs and we believe the Company is poised to achieve a number of important milestones in 2019,” noted Dr. Christian Homsy, CEO of Celyad. “We continue to be encouraged by the clinical data observed with CYAD-01 for the treatment of hematological indications. As a result, we are prioritizing the clinical development program of CYAD-01 for the treatment of relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome towards Phase 2 trials.”

2019 Milestones

Building upon its 2018 accomplishments, the Company intends to achieve the following key milestones over the next 12 months:

 

   

Report additional data from the Phase 1 dose-escalation THINK trial for CYAD-01 in r/r AML or MDS patients, including initial data from the schedule optimization portion of the trial;

 

   

Complete enrollment for and report initial data from the Phase 1 dose-escalation DEPLETHINK trial evaluating CYAD-01 with preconditioning chemotherapy in r/r AML or MDS patients;

 

   

Accelerate the development strategy and refine the regulatory pathway plan for CYAD-01 for the treatment of r/r AML or MDS patients, including the initiation of a Phase 2 clinical trial;

 

   

Present in vivo preclinical data for our proprietary non-gene edited allogeneic shRNA platform and progress towards an Investigational New Drug (IND) application for the program; and

 

   

Further evaluate the potential for next-generation autologous and allogeneic NKG2D-based CAR-T therapies in the treatment of solid tumors.

 

www.celyad.com | 1


LOGO   

Press Release

07 January 2019

7:00am CET

 

Clinical Update for CYAD-01 in Hematological Malignancies

Celyad’s lead clinical candidate, CYAD-01, is currently being evaluated in multiple clinical trials for the treatment of patients with hematological malignancies, including r/r AML and MDS.

THINK Phase 1 Trial

 

   

In December 2018 at the 60 th Annual American Society of Hematology meeting, Celyad reported an encouraging objective response rate in r/r AML patients of 38% (three out of eight) from the THINK Phase 1 trial, evaluating CYAD-01 without preconditioning chemotherapy.

 

   

Preliminary data for the last two patients enrolled and treated at dose level 3 show one patient with relapsing MDS with refractory anemia with excess blasts achieved a marrow complete response after two injections of CYAD-01, while the second patient with r/r AML experienced disease stabilization after the first cycle of CYAD-01. Both patients plan to receive a second (consolidation) cycle of therapy.

 

   

Additional results from the THINK Phase 1 trial are expected to be announced during the first half of 2019.

Dr. Frédéric Lehmann, Vice President of Clinical Development and Medical Affairs at Celyad, commented, “Current clinical data for the last two patients treated at dose level 3 of the THINK trial provide additional support for the further development of CYAD-01 as a potential treatment of r/r AML and MDS and our decision to rapidly identify the best clinical path forward for the investigational therapy.”

DEPLETHINK Phase 1 Trial

 

   

In December 2018, Celyad reported initial data from Cohort 1 of the trial, in which the administration of CYAD-01 following the preconditioning regimen of cyclophosphamide and fludarabine was well-tolerated, with no dose-limiting toxicity or treatment-related grade 3 or above adverse events observed. Based on these preliminary safety data from Cohort 1, enrollment has been initiated in Cohort 2 of the trial. Preliminary data from the DEPLETHINK Phase 1 trial are expected in mid-2019.

EPITHINK Phase 1 Trial

 

   

Based on the data generated to date for CYAD-01 from the THINK trial and the recent update in the treatment landscape for newly diagnosed AML patients, the Company has put the EPITHINK trial on hold to focus its efforts on the development of CYAD-01 for the treatment of r/r AML patients. Celyad plans to reassess the opportunity for CYAD-01 in newly diagnosed AML patients after the optimal treatment design for the therapy is determined. The EPITHINK Phase 1 dose-escalation trial planned to assess the administration of CYAD-01 concurrently with 5-azacytidine in treatment-naïve and/or elderly AML patients ineligible for intensive treatment.

 

www.celyad.com | 2


LOGO   

Press Release

07 January 2019

7:00am CET

 

Solid Tumor Clinical Program Update

 

   

In November 2018 at the Society for Immunotherapy of Cancer 33 rd Annual Meeting, the Company reported an interim analysis from the Phase 1 dose-escalation SHRINK trial evaluating the safety and activity of CYAD-01 administered concurrently with FOLFOX chemotherapy (a combination of 5-fluorouracil, leucovorin and oxaliplatin) in patients with metastatic colorectal cancer (mCRC). Follow-up assessment of patients based on response evaluation criteria in solid tumors (RECIST) from dose level 1 of the trial confirmed one patient achieved a partial response and two patients experienced disease stabilization. Full data from the SHRINK Phase 1 trial are expected in 2019.

 

   

In December 2018, Celyad initiated the alloSHRINK trial evaluating the non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable mCRC. To date, no relevant treatment related toxicity has been observed in the first subject enrolled in the trial. Topline data from alloSHRINK trial are expected in the second half of 2019.

*** END***

About CYAD-01 and CYAD-101

CYAD-01 is an investigational CAR-T therapy in which a patient’s T cells are engineered to express the chimeric antigen receptor NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands expressed on tumor cells. CYAD-101 is an investigational, non-gene edited, allogeneic (donor derived) CAR-T therapy that co-expresses the chimeric antigen receptor NKG2D of CYAD-01 and the novel inhibitory peptide TIM (T cell receptor [TCR] Inhibiting Molecule). The expression of TIM reduces signaling of the TCR complex, which is responsible for Graft versus Host Disease (GvHD) and could therefore reduce or eliminate GvHD in patients treated with CYAD-101.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), is currently being evaluated in a Phase I dose escalation clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). The safety and clinical activity of the CYAD-01 therapy concurrently administered with standard-of-care treatments or preconditioning chemotherapy is also being assessed in a full clinical development program focused on acute myeloid leukemia and colorectal cancer. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

 

www.celyad.com | 3


LOGO   

Press Release

07 January 2019

7:00am CET

 

For more information, please contact:

Celyad

Investors@celyad.com

Filippo Petti, Chief Financial Officer

Communications@celyad.com

Alexandrine Hazard, Corporate Communications Associate - T: +32(0) 10 39 41 58

 

 

For Belgium: Comfi

Sabine Leclercq - T.: +32 (0)2 290 90 91 celyad@comfi.be

 

 

For France: NewCap

Pierre Laurent and Nicolas Mérigeau - T: + 33(0)1 44 71 94 94 - celyad@newcap.eu

 

 

For the U.S.: LifeSci Advisors

Daniel Ferry – T.: +1 (617) 535 7746 daniel@lifesciadvisors.com

Public Relations: Sara Zelkovic – T:+1 (646) 876 4933 - sara@lifescipublicrelations.com

 

 

Forward-looking statements

This release may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and CYAD-101; the ongoing and planned clinical development of CYAD-01 and CYAD-101, including the timing of trials, enrollment, data readouts and presentations; the clinical and commercial potential of CYAD-01 and CYAD-101 and the adequacy of Celyad’s financial resources; Celyad’s worldwide development and commercialization rights to CYAD-101; the ongoing and planned clinical and commercial potential and development of its shRNA technology; Celyad’s financial condition, results of operation and business outlook; and Celyad’s expected cash burn. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01 and CYAD-101 drug product candidates. These results may not be repeated or observed in ongoing or future studies involving the CYAD-01 and CYAD-101 drug product candidates. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our mAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01 and CYAD-101 in the United States and Europe and subsequent commercial success of CYAD-01 and CYAD-101, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and

 

www.celyad.com | 4


LOGO   

Press Release

07 January 2019

7:00am CET

 

technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to maintain and enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing therapies and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and other risks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on April 6, 2018 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

 

www.celyad.com | 5

Exhibit 99.2 Pioneering breakthrough therapies for patients with life-threatening diseases Corporate Presentation January 2019Exhibit 99.2 Pioneering breakthrough therapies for patients with life-threatening diseases Corporate Presentation January 2019


Forward-Looking Statements This release may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and CYAD-101 and the mAb manufacturing method used to manufacture this drug product candidate; statements concerning the ongoing and planned clinical development of CYAD-01 and CYAD-101, including the timing of trials, enrollment, data readouts and presentations; the clinical and commercial potential of CYAD-01 and CYAD-101 and the adequacy of Celyad’s financial resources; statements concerning Celyad’s exclusive agreement with Horizon Discovery Group; the clinical and commercial potential of its shRNA technology; Celyad’s financial condition, results of operation and business outlook; and Celyad’s expected cash burn. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01 and CYAD-101 drug product candidates. These results may not be repeated or observed in ongoing or future studies involving the CYAD-01 and CYAD-101 drug product candidates. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our mAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01 and CYAD-101 in the United States and Europe and subsequent commercial success of CYAD-01 and CYAD-101, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to maintain and enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing therapies and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and other risks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on April 6, 2018 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. 2Forward-Looking Statements This release may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and CYAD-101 and the mAb manufacturing method used to manufacture this drug product candidate; statements concerning the ongoing and planned clinical development of CYAD-01 and CYAD-101, including the timing of trials, enrollment, data readouts and presentations; the clinical and commercial potential of CYAD-01 and CYAD-101 and the adequacy of Celyad’s financial resources; statements concerning Celyad’s exclusive agreement with Horizon Discovery Group; the clinical and commercial potential of its shRNA technology; Celyad’s financial condition, results of operation and business outlook; and Celyad’s expected cash burn. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual results, financial condition and liquidity, performance or achievements of Celyad, or industry results, to differ materially from those expressed or implied by such forward-looking statements. In particular it should be noted that the data summarized above are preliminary in nature. There is limited data concerning safety and clinical activity following treatment with the CYAD-01 and CYAD-101 drug product candidates. These results may not be repeated or observed in ongoing or future studies involving the CYAD-01 and CYAD-101 drug product candidates. These forward-looking statements are further qualified by important factors and risks, which could cause actual results to differ materially from those in the forward-looking statements, including statements about: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance drug product candidates into, and successfully complete, clinical trials; our ability to successfully manufacture drug product for our clinical trials, including with our mAb manufacturing process and with respect to manufacturing drug product with the desired number of T cells under our clinical trial protocols; our reliance on the success of our drug product candidates, including our dependence on the regulatory approval of CYAD-01 and CYAD-101 in the United States and Europe and subsequent commercial success of CYAD-01 and CYAD-101, both of which may never occur; the timing or likelihood of regulatory filings and approvals; our ability to develop sales and marketing capabilities; the commercialization of our drug product candidates, if approved; the pricing and reimbursement of our drug product candidates, if approved; the implementation of our business model, strategic plans for our business, drug product candidates and technology; the scope of protection we are able to establish and maintain for intellectual property rights covering our drug product candidates and technology; our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; cost associated with enforcing or defending intellectual property infringement, misappropriation or violation; product liability; and other claims; regulatory development in the United States, the European Union, and other jurisdictions; estimates of our expenses, future revenues, capital requirements and our needs for additional financing; the potential benefits of strategic collaboration agreements and our ability to maintain and enter into strategic arrangements; our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug product candidates, if approved; our financial performance; developments relating to our competitors and our industry, including competing therapies and statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance. A further list and description of these risks, uncertainties and other risks can be found in Celyad’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on April 6, 2018 and subsequent filings and reports by Celyad. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document and Celyad’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. 2


Company Overview Lead candidate is CYAD-01 – autologous CAR-T therapy leveraging the natural killer receptor NKG2D – currently in Phase 1 development for the treatment of hematological malignancies and solid tumors Proof of principle for CAR-T NKG2D approach supported by preliminary clinical results from Phase 1 THINK trial which demonstrated activity in patients with relapse/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) First-in-class, non-gene edited allogeneic TIM technology/NKG2D-based CAR-T candidate CYAD-101 currently in Phase 1 trial for the treatment of mCRC Developing next-generation, non-gene edited allogeneic platform based on shRNA technology Robust intellectual property position with respect to NKG2D receptor-based and allogeneic CAR-Ts 3Company Overview Lead candidate is CYAD-01 – autologous CAR-T therapy leveraging the natural killer receptor NKG2D – currently in Phase 1 development for the treatment of hematological malignancies and solid tumors Proof of principle for CAR-T NKG2D approach supported by preliminary clinical results from Phase 1 THINK trial which demonstrated activity in patients with relapse/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) First-in-class, non-gene edited allogeneic TIM technology/NKG2D-based CAR-T candidate CYAD-101 currently in Phase 1 trial for the treatment of mCRC Developing next-generation, non-gene edited allogeneic platform based on shRNA technology Robust intellectual property position with respect to NKG2D receptor-based and allogeneic CAR-Ts 3


CYAD-01 – Novel NKG2D-based CAR-T NKG2D Overview of NKG2D Target ▪ NKG2D is an activating receptor expressed on natural killer (NK) cells which plays an important role in protection against infection and cancer DAP10 ▪ The receptor binds to eight stress induced ligands including: Costimulatory domain MICA, MICB, ULBPs 1-6 ▪ NKG2D ligands are absent or expressed at low levels in CD3ζ normal tissues ▪ Expression of NKG2D ligands: Schematic of CYAD-01 ▪ Acute myeloid leukemia: 100%▪ Multiple myeloma: 10% - 60% ▪ Bladder: 97%▪ Non-small cell lung cancer: 100% The binding of eight ligands by the ▪ Chronic myeloid leukemia: 12% - 100%▪ Ovarian: 84% NKG2D receptor provides an opportunity ▪ Colorectal: 100%▪ Pancreatic: 90% to target a broad range of cancers with the novel CAR-T therapy, CYAD-01▪ Lymphoma: 12% - 44%▪ Triple negative breast: 97% 4CYAD-01 – Novel NKG2D-based CAR-T NKG2D Overview of NKG2D Target ▪ NKG2D is an activating receptor expressed on natural killer (NK) cells which plays an important role in protection against infection and cancer DAP10 ▪ The receptor binds to eight stress induced ligands including: Costimulatory domain MICA, MICB, ULBPs 1-6 ▪ NKG2D ligands are absent or expressed at low levels in CD3ζ normal tissues ▪ Expression of NKG2D ligands: Schematic of CYAD-01 ▪ Acute myeloid leukemia: 100%▪ Multiple myeloma: 10% - 60% ▪ Bladder: 97%▪ Non-small cell lung cancer: 100% The binding of eight ligands by the ▪ Chronic myeloid leukemia: 12% - 100%▪ Ovarian: 84% NKG2D receptor provides an opportunity ▪ Colorectal: 100%▪ Pancreatic: 90% to target a broad range of cancers with the novel CAR-T therapy, CYAD-01▪ Lymphoma: 12% - 44%▪ Triple negative breast: 97% 4


Advancing Clinical Pipeline Product Target Study Design Preclinical IND Submission Phase 1/2 Standalone THINK Hematological malignancies and Solid tumors w/o Preconditioning Schedule optimization THINK r/r AML / MDS w/o Preconditioning Cohort 10 Preconditioning NKG2D DEPLETHINK r/r AML / MDS CYAD-01 with CyFlu Preconditioning THINK CyFlu mCRC with CyFlu Concurrent SHRINK mCRC with FOLFOX Concurrent NKG2D alloSHRINK mCRC CYAD-101 with FOLFOX AML: Acute myeloid leukemia; mCRC: Metastatic colorectal cancer; MDS: Myelodysplastic syndrome; r/r: relapse/refractory. 5 CyFlu: cyclophosphamide and fludarabine; FOLFOX: leucovorin, fluorouracil, and oxaliplatin. Advancing Clinical Pipeline Product Target Study Design Preclinical IND Submission Phase 1/2 Standalone THINK Hematological malignancies and Solid tumors w/o Preconditioning Schedule optimization THINK r/r AML / MDS w/o Preconditioning Cohort 10 Preconditioning NKG2D DEPLETHINK r/r AML / MDS CYAD-01 with CyFlu Preconditioning THINK CyFlu mCRC with CyFlu Concurrent SHRINK mCRC with FOLFOX Concurrent NKG2D alloSHRINK mCRC CYAD-101 with FOLFOX AML: Acute myeloid leukemia; mCRC: Metastatic colorectal cancer; MDS: Myelodysplastic syndrome; r/r: relapse/refractory. 5 CyFlu: cyclophosphamide and fludarabine; FOLFOX: leucovorin, fluorouracil, and oxaliplatin.


CYAD-01 – AML / MDS ProgramCYAD-01 – AML / MDS Program


CYAD-01 Trial Designs in Hematological Malignancies (1) THINK Standalone without Preconditioning (1) THINK – Cohort 10 Schedule optimization without Preconditioning (2) DEPLETHINK Preconditioning with CyFlu CyFlu: cyclophosphamide and fludarabine. 7 (1) ClinicalTrials.gov Identifier: NCT03018405; (2) ClinicalTrials.gov Identifier: NCT03466320.CYAD-01 Trial Designs in Hematological Malignancies (1) THINK Standalone without Preconditioning (1) THINK – Cohort 10 Schedule optimization without Preconditioning (2) DEPLETHINK Preconditioning with CyFlu CyFlu: cyclophosphamide and fludarabine. 7 (1) ClinicalTrials.gov Identifier: NCT03018405; (2) ClinicalTrials.gov Identifier: NCT03466320.


Overview of THINK Phase 1 Trial for Hematological Malignancies ▪ Open-label, dose-escalation Phase 1 trial evaluating CYAD-01 without preconditioning chemotherapy or bridging therapy in relapse/refractory (r/r) hematological malignancies (1) including AML, myelodysplastic syndromes (MDS) and multiple myeloma (MM) 8 9 9 ▪ Three dose levels of CYAD-01 per injection under investigation: 3x10 ,1x10 and 3x10 ▪ One cycle comprised of three CYAD-01 injections with two-week intervals ▪ As of dose level 2, patients eligible for second cycle of three injections in absence of progressive disease ▪ Recent amendment to the trial added Cohort 10, which will assess a more frequent dosing schedule of CYAD-01 – six injections without preconditioning over two months of administration ▪ Primary endpoints of the trial include safety and tolerability with the secondary endpoint as clinical activity 8Overview of THINK Phase 1 Trial for Hematological Malignancies ▪ Open-label, dose-escalation Phase 1 trial evaluating CYAD-01 without preconditioning chemotherapy or bridging therapy in relapse/refractory (r/r) hematological malignancies (1) including AML, myelodysplastic syndromes (MDS) and multiple myeloma (MM) 8 9 9 ▪ Three dose levels of CYAD-01 per injection under investigation: 3x10 ,1x10 and 3x10 ▪ One cycle comprised of three CYAD-01 injections with two-week intervals ▪ As of dose level 2, patients eligible for second cycle of three injections in absence of progressive disease ▪ Recent amendment to the trial added Cohort 10, which will assess a more frequent dosing schedule of CYAD-01 – six injections without preconditioning over two months of administration ▪ Primary endpoints of the trial include safety and tolerability with the secondary endpoint as clinical activity 8


Review of Patient Status in THINK Trial in Hematological Malignancies Sixteen r/r AML, MDS, MM patients (6/3/7 at dose levels 1/2/3) Three MM patients at dose Thirteen r/r AML or MDS patients level 1 had no clinical response Three r/r AML or MDS patients (3/3/7 at dose levels 1/2/3) (2) were non-evaluable (1) Ten r/r AML or MDS patients evaluable per protocol ▪ One patient experienced a marrow CR at dose level 3 ▪ One patient experienced CR at dose level 1 – patient bridged to allo-HSCT on day +97 and remains in CR for over 15 months h MRD- ▪ Two patients experienced CR at dose level 1 and dose level 3, respectively i ▪ Two patients treated at dose level two achieved SD with relevant bone marrow blast decrease ▪ One patient achieved SD for six months with bone marrow blast decrease from 9.8% to 5.5%, patient received second cycle of CYAD-01 and experienced reduction in bone marrow blast from 12.5% to 5.8% ▪ One patient achieved SD for three months with bone marrow blast decrease from 24% to 10% and hematologic improvement ▪ Two patients at dose level 3 had SD; both patients are scheduled to receive second cycle of CYAD-01 ▪ Two patients had PD – one at dose level 2 and one at dose level 3 40% of patients evaluable for response achieved a CR/CRh/CRi and 60% experienced anti-leukemic activity Interim results as of January 4, 2019. CR: Complete response; CR : Complete response with partial hematological recovery; CR : complete response with incomplete marrow recovery; SD: Stable disease; PD: Progressive disease. 9 h i (1) Patient received at least one cycle (three injections) of CYAD-01; (2) Patient received less than one cycle (three injections) of CYAD-01. Review of Patient Status in THINK Trial in Hematological Malignancies Sixteen r/r AML, MDS, MM patients (6/3/7 at dose levels 1/2/3) Three MM patients at dose Thirteen r/r AML or MDS patients level 1 had no clinical response Three r/r AML or MDS patients (3/3/7 at dose levels 1/2/3) (2) were non-evaluable (1) Ten r/r AML or MDS patients evaluable per protocol ▪ One patient experienced a marrow CR at dose level 3 ▪ One patient experienced CR at dose level 1 – patient bridged to allo-HSCT on day +97 and remains in CR for over 15 months h MRD- ▪ Two patients experienced CR at dose level 1 and dose level 3, respectively i ▪ Two patients treated at dose level two achieved SD with relevant bone marrow blast decrease ▪ One patient achieved SD for six months with bone marrow blast decrease from 9.8% to 5.5%, patient received second cycle of CYAD-01 and experienced reduction in bone marrow blast from 12.5% to 5.8% ▪ One patient achieved SD for three months with bone marrow blast decrease from 24% to 10% and hematologic improvement ▪ Two patients at dose level 3 had SD; both patients are scheduled to receive second cycle of CYAD-01 ▪ Two patients had PD – one at dose level 2 and one at dose level 3 40% of patients evaluable for response achieved a CR/CRh/CRi and 60% experienced anti-leukemic activity Interim results as of January 4, 2019. CR: Complete response; CR : Complete response with partial hematological recovery; CR : complete response with incomplete marrow recovery; SD: Stable disease; PD: Progressive disease. 9 h i (1) Patient received at least one cycle (three injections) of CYAD-01; (2) Patient received less than one cycle (three injections) of CYAD-01.


Interim Analysis from THINK Trial Demonstrates Clinical Activity of CYAD-01 Without Preconditioning Chemotherapy Change in Bone Marrow Blast Count from Baseline (%) 102-506 ▪ Clinical activity observed 100% across all three dose 80% levels of CYAD-01 202-505 60% ▪ Potential induction of PR 40% post-hematological relapse following second 20% cycle of CYAD-01 in SD SD 0% (2) patient 202-506 202-511 202-512 SD SD CR CR CR mCR h i i -20% ▪ Bone marrow blasts -40% show no loss of NKG2D DL-1 202-506 ligand expression -60% 101-502 DL-2 following treatment with 202-501 101-501 -80% 102-505 CYAD-01 DL-3 (1) 102-507 -100% Interim results as of January 4, 2019. CRh: Complete response with partial hematological recovery; CRi: Complete response with incomplete marrow recovery; mCR: Marrow complete response; PR: Partial response; SD: Stable disease. (1) Patient 102-507 – patient with relapsing MDS with refractory anemia with excess blasts (RAEB). 10 (2) Patient 202-506 achieved relevant bone marrow blast decrease following second cycle of CYAD-01 without preconditioning chemotherapy (not shown). Change from baseline (%)Interim Analysis from THINK Trial Demonstrates Clinical Activity of CYAD-01 Without Preconditioning Chemotherapy Change in Bone Marrow Blast Count from Baseline (%) 102-506 ▪ Clinical activity observed 100% across all three dose 80% levels of CYAD-01 202-505 60% ▪ Potential induction of PR 40% post-hematological relapse following second 20% cycle of CYAD-01 in SD SD 0% (2) patient 202-506 202-511 202-512 SD SD CR CR CR mCR h i i -20% ▪ Bone marrow blasts -40% show no loss of NKG2D DL-1 202-506 ligand expression -60% 101-502 DL-2 following treatment with 202-501 101-501 -80% 102-505 CYAD-01 DL-3 (1) 102-507 -100% Interim results as of January 4, 2019. CRh: Complete response with partial hematological recovery; CRi: Complete response with incomplete marrow recovery; mCR: Marrow complete response; PR: Partial response; SD: Stable disease. (1) Patient 102-507 – patient with relapsing MDS with refractory anemia with excess blasts (RAEB). 10 (2) Patient 202-506 achieved relevant bone marrow blast decrease following second cycle of CYAD-01 without preconditioning chemotherapy (not shown). Change from baseline (%)


Summary of CYAD-01 r/r AML/MDS Program THINK THINK – Cohort 10 DEPLETHINK ▪ Encouraging clinical activity ▪ Amendment will assess a ▪ Dose escalation trial will with 40% of patients more frequent dosing evaluate a single injection of achieving CR and anti- schedule of CYAD-01 CYAD-01 following treatment leukemic activity observed in with the standard ▪ Plans to evaluate six 60% of patients preconditioning regimen of injections of CYAD-01 CyFlu ▪ CYAD-01 without without preconditioning over preconditioning two cycles▪ Preliminary data from initial chemotherapy generally dose level showed regimen is ▪ First cycle will include three injections of CYAD-01 reported to be well-tolerated well tolerated, with no DLTs or separated by one-week treatment-related grade 3 or ▪ Additional results from dose intervals; the second cycle by above AEs observed level 3 expected in first half two-week intervals 2019▪ Preliminary data from the trial ▪ Preliminary data are expected are expected in mid-2019 in first half 2019 11 AEs: Adverse events; CR: Complete response including either CR or CRh or CRi; DLTs: Dose-limiting toxicity.Summary of CYAD-01 r/r AML/MDS Program THINK THINK – Cohort 10 DEPLETHINK ▪ Encouraging clinical activity ▪ Amendment will assess a ▪ Dose escalation trial will with 40% of patients more frequent dosing evaluate a single injection of achieving CR and anti- schedule of CYAD-01 CYAD-01 following treatment leukemic activity observed in with the standard ▪ Plans to evaluate six 60% of patients preconditioning regimen of injections of CYAD-01 CyFlu ▪ CYAD-01 without without preconditioning over preconditioning two cycles▪ Preliminary data from initial chemotherapy generally dose level showed regimen is ▪ First cycle will include three injections of CYAD-01 reported to be well-tolerated well tolerated, with no DLTs or separated by one-week treatment-related grade 3 or ▪ Additional results from dose intervals; the second cycle by above AEs observed level 3 expected in first half two-week intervals 2019▪ Preliminary data from the trial ▪ Preliminary data are expected are expected in mid-2019 in first half 2019 11 AEs: Adverse events; CR: Complete response including either CR or CRh or CRi; DLTs: Dose-limiting toxicity.


CYAD-01 – Solid Tumor ProgramCYAD-01 – Solid Tumor Program


CYAD-01 Trial Designs in Solid Tumor (1) THINK Standalone without Preconditioning (1) THINK CyFlu Cohort Preconditioning with CyFlu 1st CYAD-01 2nd CYAD-01 3rd CYAD-01 FOLFOX Washout period (2) SHRINK D-21 D-7 D1 D99 D31 Apheresis Concurrent with FOLFOX Tumor assessment Surgery 13 (1) ClinicalTrials.gov Identifier: NCT03018405; (2) ClinicalTrials.gov Identifier: NCT03310008. CYAD-01 Trial Designs in Solid Tumor (1) THINK Standalone without Preconditioning (1) THINK CyFlu Cohort Preconditioning with CyFlu 1st CYAD-01 2nd CYAD-01 3rd CYAD-01 FOLFOX Washout period (2) SHRINK D-21 D-7 D1 D99 D31 Apheresis Concurrent with FOLFOX Tumor assessment Surgery 13 (1) ClinicalTrials.gov Identifier: NCT03018405; (2) ClinicalTrials.gov Identifier: NCT03310008.


CYAD-01 in Solid Tumor – Best Clinical Responses SHRINK THINK THINK CyFlu with concurrent without preconditioning with preconditioning FOLFOX DL-1 DL-2 DL-3 DL-1 8 9 9 8 8 3x10 1x10 3x10 3x10 1x10 N=2 N=3 N=4 N=4 N=6 Best overall response Complete response - - - - Assessment Partial response - - - **1*° Ongoing Stable disease 1 CRC * 1 OVA * 2 CRC * **2*° Progressive disease 3 2 3 - † Non evaluable - 1 1 - Interim results as of January 4, 2019. * Confirmed by RECIST criteria. ° One complete pathological response (pCR) and two partial pathological responses (pPR) reported at prior assessment. † Non-evaluable for clinical activity evaluation. Withdrawn from study following one CYAD-01 injection. CRC: Colorectal cancer; OVA: Ovarian cancer. DL: Dose level. 14CYAD-01 in Solid Tumor – Best Clinical Responses SHRINK THINK THINK CyFlu with concurrent without preconditioning with preconditioning FOLFOX DL-1 DL-2 DL-3 DL-1 8 9 9 8 8 3x10 1x10 3x10 3x10 1x10 N=2 N=3 N=4 N=4 N=6 Best overall response Complete response - - - - Assessment Partial response - - - **1*° Ongoing Stable disease 1 CRC * 1 OVA * 2 CRC * **2*° Progressive disease 3 2 3 - † Non evaluable - 1 1 - Interim results as of January 4, 2019. * Confirmed by RECIST criteria. ° One complete pathological response (pCR) and two partial pathological responses (pPR) reported at prior assessment. † Non-evaluable for clinical activity evaluation. Withdrawn from study following one CYAD-01 injection. CRC: Colorectal cancer; OVA: Ovarian cancer. DL: Dose level. 14


Summary of CYAD-01 mCRC Program THINK SHRINK THINK CyFlu ▪ Standalone CYAD-01 without ▪ Early data shows CYAD-01 is ▪ Encouraging activity preconditioning was well well tolerated following observed in first dose level of tolerated standard preconditioning CYAD-01 with FOLFOX – regimen of CyFlu partial response achieved by ▪ Provides potential RECIST assessment opportunity to combine with ▪ Preliminary translational data alternative IO agents in solid suggest an improvement in ▪ Concurrent treatment of tumor the cell expansion of CYAD- CYAD-01 with FOLFOX 01 induced by preconditioning appears to be well tolerated ▪ Observation of dose-effect with disease stabilization ▪ Full data from cohort (three ▪ Full data expected in mid- seen across different dose patients) expected in mid- 2019 levels and indications 2019 15Summary of CYAD-01 mCRC Program THINK SHRINK THINK CyFlu ▪ Standalone CYAD-01 without ▪ Early data shows CYAD-01 is ▪ Encouraging activity preconditioning was well well tolerated following observed in first dose level of tolerated standard preconditioning CYAD-01 with FOLFOX – regimen of CyFlu partial response achieved by ▪ Provides potential RECIST assessment opportunity to combine with ▪ Preliminary translational data alternative IO agents in solid suggest an improvement in ▪ Concurrent treatment of tumor the cell expansion of CYAD- CYAD-01 with FOLFOX 01 induced by preconditioning appears to be well tolerated ▪ Observation of dose-effect with disease stabilization ▪ Full data from cohort (three ▪ Full data expected in mid- seen across different dose patients) expected in mid- 2019 levels and indications 2019 15


CYAD-101 ProgramCYAD-101 Program


Background on CYAD-101 ▪ CYAD-101 is Celyad’s first non-gene edited, allogeneic CAR-T clinical candidate ▪ CYAD-101 co-expresses the company’s CYAD-01 CAR-T construct and the novel inhibitory peptide TIM (T cell receptor [TCR] Inhibiting Molecule) within a single vector ▪ In November 2018, the Company initiated the Phase 1 alloSHRINK trial which will evaluate CYAD-101 administered concurrently with standard-of-care FOLFOX chemotherapy for the treatment of patients with mCRC ▪ Preliminary results from the trial are expected in second half 2019 Schematic of CYAD-101 vector 17Background on CYAD-101 ▪ CYAD-101 is Celyad’s first non-gene edited, allogeneic CAR-T clinical candidate ▪ CYAD-101 co-expresses the company’s CYAD-01 CAR-T construct and the novel inhibitory peptide TIM (T cell receptor [TCR] Inhibiting Molecule) within a single vector ▪ In November 2018, the Company initiated the Phase 1 alloSHRINK trial which will evaluate CYAD-101 administered concurrently with standard-of-care FOLFOX chemotherapy for the treatment of patients with mCRC ▪ Preliminary results from the trial are expected in second half 2019 Schematic of CYAD-101 vector 17


CYAD-101 Leverages TIM-mediated Inhibition of TCR Signaling CYAD-101 Endogenous TIM-incorporating NKG2D CAR The expression of TIM TCR/CD3 complex TCR/CD3 complex results in the competitive inhibition of CD3z and reduces signalling of the TCR complex leading to the potential reduction or elimination of Graft versus Host Disease (GvHD) in patients treated with CYAD-101 18CYAD-101 Leverages TIM-mediated Inhibition of TCR Signaling CYAD-101 Endogenous TIM-incorporating NKG2D CAR The expression of TIM TCR/CD3 complex TCR/CD3 complex results in the competitive inhibition of CD3z and reduces signalling of the TCR complex leading to the potential reduction or elimination of Graft versus Host Disease (GvHD) in patients treated with CYAD-101 18


Allogeneic shRNA Platform Allogeneic shRNA Platform


Developing a Next Generation, Non-Gene Edited Platform for CAR-T ▪ In October 2018, Celyad announced it had entered into an exclusive agreement with Horizon Discovery Group for the use of its shRNA technology to generate a novel, next-generation, non-gene-edited allogeneic platform for CAR-T therapies ▪ shRNA platform should provide flexibility to combine with NKG2D receptor as well as CARs targeting public antigens including CD19, BCMA, etc. ▪ Opportunity to establish a single vector approach to generate allogeneic CAR-T cells ▪ Builds upon Celyad’s “All-in-One Vector” approach ▪ Preliminary in vitro outcome compares favorably to gene editing methods to inhibit TCR expression ▪ Additional in vivo data from the platform are expected during first quarter 2019 20Developing a Next Generation, Non-Gene Edited Platform for CAR-T ▪ In October 2018, Celyad announced it had entered into an exclusive agreement with Horizon Discovery Group for the use of its shRNA technology to generate a novel, next-generation, non-gene-edited allogeneic platform for CAR-T therapies ▪ shRNA platform should provide flexibility to combine with NKG2D receptor as well as CARs targeting public antigens including CD19, BCMA, etc. ▪ Opportunity to establish a single vector approach to generate allogeneic CAR-T cells ▪ Builds upon Celyad’s “All-in-One Vector” approach ▪ Preliminary in vitro outcome compares favorably to gene editing methods to inhibit TCR expression ▪ Additional in vivo data from the platform are expected during first quarter 2019 20


Benchmarking the shRNA Approach Against Gene-Editing Knockdown of TCR in Primary T cells Equivalent knockdown compared to gene editing Primary human T cells selected after transduction with a retroviral vector encoding a single shRNA targeting CD3z shows equivalent knockdown of the TCR/CD3 complex as T cells gene edited with CRISPR/Cas9 to eliminate CD3z 21Benchmarking the shRNA Approach Against Gene-Editing Knockdown of TCR in Primary T cells Equivalent knockdown compared to gene editing Primary human T cells selected after transduction with a retroviral vector encoding a single shRNA targeting CD3z shows equivalent knockdown of the TCR/CD3 complex as T cells gene edited with CRISPR/Cas9 to eliminate CD3z 21


ManufacturingManufacturing


Celyad’s Manufacturing Expertise ▪ 1,100 sq. meter facility in AML mCRC Mont-Saint-Guibert is equipped to supply all of Celyad’s expected clinical trials as well as support over 1,000 patients annually ▪ Manufacturing success rate of 93% (n=29) since implementation of last amendment ▪ Optimized process has led to substantial log increase in cell yield versus academic process 23Celyad’s Manufacturing Expertise ▪ 1,100 sq. meter facility in AML mCRC Mont-Saint-Guibert is equipped to supply all of Celyad’s expected clinical trials as well as support over 1,000 patients annually ▪ Manufacturing success rate of 93% (n=29) since implementation of last amendment ▪ Optimized process has led to substantial log increase in cell yield versus academic process 23


Strategy and FinancialsStrategy and Financials


Strong Intellectual Property Key U.S. Patents Strategic Validation (1) ▪ Allogeneic T-Cell Technology ▪ T-cell receptor deficient T-cell ▪ In May 2017, Celyad granted Novartis a non- compositions exclusive license for allogeneic TCR-deficient ▪ Method of producing T-cell receptor CAR-T cells patents related to two deficient T-cells expressing a chimeric undisclosed targets receptor ▪ Deal terms: Undisclosed upfront payment ▪ Chimeric NK receptor and methods for with $96 million in milestones plus royalties (2) treating cancer on commercial U.S. sales ▪ Celyad retains all rights to grant further licenses to the undisclosed targets (1) Granted U.S. Patents: No. 9,181,527, No. 9,938,497, No. 9,957,480, No. 9,663,763, No. 9,822,340 and No. 9,821,011. (2) Granted U.S. Patent: No. 9,273,283. 25Strong Intellectual Property Key U.S. Patents Strategic Validation (1) ▪ Allogeneic T-Cell Technology ▪ T-cell receptor deficient T-cell ▪ In May 2017, Celyad granted Novartis a non- compositions exclusive license for allogeneic TCR-deficient ▪ Method of producing T-cell receptor CAR-T cells patents related to two deficient T-cells expressing a chimeric undisclosed targets receptor ▪ Deal terms: Undisclosed upfront payment ▪ Chimeric NK receptor and methods for with $96 million in milestones plus royalties (2) treating cancer on commercial U.S. sales ▪ Celyad retains all rights to grant further licenses to the undisclosed targets (1) Granted U.S. Patents: No. 9,181,527, No. 9,938,497, No. 9,957,480, No. 9,663,763, No. 9,822,340 and No. 9,821,011. (2) Granted U.S. Patent: No. 9,273,283. 25


Upcoming Milestones First Quarter 2019 First Half 2019 Second Half 2019 ▪ In-vivo data from next-▪ Updated data from dose level 3 ▪ Preliminary data from generation, allogeneic shRNA and initial data from Cohort 10 of alloSHRINK trial evaluating platform THINK trial evaluating CYAD-01 allogeneic CYAD-01 with without preconditioning in r/r FOLFOX chemotherapy in AML mCRC ▪ Preliminary data from dose-▪ Initiation of Phase 2 clinical escalation DEPLETHINK trial trial evaluating evaluating CYAD-01 following CYAD-01 in r/r AML preconditioning in r/r AML ▪ Updated data from THINK CyFlu and SHRINK trials evaluating CYAD-01 in mCRC 26Upcoming Milestones First Quarter 2019 First Half 2019 Second Half 2019 ▪ In-vivo data from next-▪ Updated data from dose level 3 ▪ Preliminary data from generation, allogeneic shRNA and initial data from Cohort 10 of alloSHRINK trial evaluating platform THINK trial evaluating CYAD-01 allogeneic CYAD-01 with without preconditioning in r/r FOLFOX chemotherapy in AML mCRC ▪ Preliminary data from dose-▪ Initiation of Phase 2 clinical escalation DEPLETHINK trial trial evaluating evaluating CYAD-01 following CYAD-01 in r/r AML preconditioning in r/r AML ▪ Updated data from THINK CyFlu and SHRINK trials evaluating CYAD-01 in mCRC 26


Financial Snapshot ▪ Cash and short-term investments: €56 million as of September 30, 2018 ▪ Current cash expected to be sufficient to support the company’s activities into mid-2020 ▪ Basic Shares Outstanding: 11.9 million ▪ Ticker: Nasdaq (CYAD) and Euronext Paris & Brussels (CYAD.BR) 27Financial Snapshot ▪ Cash and short-term investments: €56 million as of September 30, 2018 ▪ Current cash expected to be sufficient to support the company’s activities into mid-2020 ▪ Basic Shares Outstanding: 11.9 million ▪ Ticker: Nasdaq (CYAD) and Euronext Paris & Brussels (CYAD.BR) 27


Proposed Roadmap to Success in CAR-T Beyond Tomorrow ▪ “Crack the code” in solid tumors with an NKG2D- Today based CAR-T therapy ▪ Leverage our leading through well-established allogeneic approach and novel combination including CYAD-101, regimens to pursue ▪ Accelerate the clinical next-generation shRNA multiple indications development program for platform and broad CYAD-01 for the allogeneic IP to become treatment of r/r AML and elite player within the field focus on path to commercialization 28Proposed Roadmap to Success in CAR-T Beyond Tomorrow ▪ “Crack the code” in solid tumors with an NKG2D- Today based CAR-T therapy ▪ Leverage our leading through well-established allogeneic approach and novel combination including CYAD-101, regimens to pursue ▪ Accelerate the clinical next-generation shRNA multiple indications development program for platform and broad CYAD-01 for the allogeneic IP to become treatment of r/r AML and elite player within the field focus on path to commercialization 28


Thank youThank you